Zobrazeno 1 - 10
of 16
pro vyhledávání: '"M. E. R. O'brien"'
Autor:
X, Wu, R, Kumar, C, Milner-Watts, D, Walder, N M L, Battisti, A, Minchom, J, Bhosle, M E R, O'Brien
Publikováno v:
Clinical Oncology. 35:e163-e172
The standard evaluation of older lung cancer or mesothelioma patients for systemic anti-cancer treatment, based on performance status, is inaccurate. We used the G8 questionnaire to assess a patient's fitness for chemotherapy and explored the correla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a47f1166e7d2f50b8c47b587d1a29a0a
https://doi.org/10.1016/j.clon.2022.10.020
https://doi.org/10.1016/j.clon.2022.10.020
Autor:
Natalie Compton, E. M Paul, C. F Xu, A. B Suttle, M. E. R O'Brien, Miguel A. Villalona-Calero, Ravi Salgia, Lone Ottesen, Ruth Plummer, Kari Kendra
Publikováno v:
Molecular Cancer Therapeutics. 14:461-469
This study was designed to evaluate the safety, pharmacokinetics, and clinical activity of pazopanib combined with paclitaxel to determine the recommended phase II dose in the first-line setting in patients with advanced solid tumors. Patients were e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c01f6ea74db49967e2e809cdb2a0412
https://doi.org/10.1158/1535-7163.mct-14-0431
https://doi.org/10.1158/1535-7163.mct-14-0431
Autor:
M E R O'Brien, A Borthwick, A Rigg, A Leary, L Assersohn, K Last, S Tan, S Milan, D Tait, I E Smith
Publikováno v:
British Journal of Cancer
No national benchmark figures exist for early mortality due to chemotherapy unlike for surgical interventions. Deaths within 30 days of chemotherapy during a 6-month period were identified from the Royal Marsden Hospital electronic patient records. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a660a9580787eff787ae55a529a1bf97
https://doi.org/10.1038/sj.bjc.6603498
https://doi.org/10.1038/sj.bjc.6603498
Autor:
Andrew Webb, M. E. R. O'brien
Publikováno v:
British Journal of Cancer. 78:159-162
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a237fc349d1dbb968e278118858a6efc
https://doi.org/10.1038/bjc.1998.458
https://doi.org/10.1038/bjc.1998.458
Autor:
I. E. Smith, M. E. R. O'brien
Publikováno v:
Current Opinion in Obstetrics and Gynecology. 8:21-26
Randomized trials with long follow-up confirm the beneficial effect of adjuvant chemotherapy in most groups of patients with operable breast cancer. The use of chemotherapy in large tumours before surgery does not appear to jeopardize survival. High-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fba6f38426a4a977ee39897c7cce0b9c
https://doi.org/10.1097/00001703-199602000-00006
https://doi.org/10.1097/00001703-199602000-00006
Publikováno v:
European journal of cancer care. 22(1)
International and UK data suggest that there are ethnic differences in survival for some malignancies. The aim of the present study was to identify any health inequalities related to lung cancer and ethnicity. Data on 423 patients with a diagnosis of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::06adeb18e9e3917c61562f6f72d586f4
https://pubmed.ncbi.nlm.nih.gov/22738286
https://pubmed.ncbi.nlm.nih.gov/22738286
Autor:
M E R, O'Brien, J S, Myerson, J I G, Coward, M, Puglisi, L, Trani, A, Wotherspoon, B, Sharma, G, Cook, S, Ashley, R, Gunapala, S, Chua, S, Popat
Publikováno v:
European journal of cancer (Oxford, England : 1990). 48(1)
The aim of this study was to assess if (18)F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)-CT scanning could minimise the time non-responding patients were exposed to erlotinib (Tarceva).Patients were selected for clinical factors that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::391f3e79135db1e01a18e5eb0dfd036e
https://pubmed.ncbi.nlm.nih.gov/22119198
https://pubmed.ncbi.nlm.nih.gov/22119198
Autor:
Mark Verrill, R H de Boer, S.R.D. Johnston, Paul Ellis, I. E. Smith, A Saini, M E R O'Brien, G. Walsh, S. Ashley, J Prendiville
Publikováno v:
Breast (Edinburgh, Scotland). 9(3)
Despite the introduction of systemic chemotherapy, inflammatory breast cancer (IBC) remains a disease with a poor prognosis. We performed this phase II study to evaluate the efficacy of infusional chemotherapy as initial treatment in patients with IB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fa7867b06a62990de2b1db60843b15a
https://pubmed.ncbi.nlm.nih.gov/14731839
https://pubmed.ncbi.nlm.nih.gov/14731839
Autor:
M E R, O'Brien, T, Splinter, E F, Smit, B, Biesma, M, Krzakowski, V C G, Tjan-Heijnen, A, Van Bochove, J, Stigt, M J A, Smid-Geirnaerdt, C, Debruyne, C, Legrand, G, Giaccone
Publikováno v:
European journal of cancer (Oxford, England : 1990). 39(10)
The aim of this study was to document the activity and toxicity of paclitaxel (Taxol)/carboplatin when used as induction chemotherapy in patients with stage IIIA N2 non-small cell lung cancer (NSCLC) prior to definitive local treatment within a large
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dae39b768d7333fbac8c37b9692e9c0c
https://pubmed.ncbi.nlm.nih.gov/12826045
https://pubmed.ncbi.nlm.nih.gov/12826045
Publikováno v:
Postgraduate Medical Journal. 70:759-761
Summary There is a dose-effect relationship between doxorubicin and the incidence of symptomatic cardiac failure. It is generally thought that doses below 500-550 mg/m2 are safe but, when objective measures of cardiac function are used, it becomes ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dd0baa3fa178321e818105d28481dd8
https://doi.org/10.1136/pgmj.70.828.759
https://doi.org/10.1136/pgmj.70.828.759